217 related articles for article (PubMed ID: 15953722)
1. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M
Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.
Noe MC; Natarajan V; Snow SL; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Carty TJ; Barberia JA; Sweeney FJ; Liras JL; Vaughn M; Hardink JR; Hawkins JM; Tokar C
Bioorg Med Chem Lett; 2005 Jun; 15(11):2808-11. PubMed ID: 15911259
[TBL] [Abstract][Full Text] [Related]
3. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
5. A novel series of highly selective inhibitors of MMP-3.
Whitlock GA; Dack KN; Dickinson RP; Lewis ML
Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
[TBL] [Abstract][Full Text] [Related]
7. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
[TBL] [Abstract][Full Text] [Related]
8. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.
Yao W; Wasserman ZR; Chao M; Reddy G; Shi E; Liu RQ; Covington MB; Arner EC; Pratta MA; Tortorella M; Magolda RL; Newton R; Qian M; Ribadeneira MD; Christ D; Wexler RR; Decicco CP
J Med Chem; 2001 Oct; 44(21):3347-50. PubMed ID: 11585439
[TBL] [Abstract][Full Text] [Related]
11. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
[TBL] [Abstract][Full Text] [Related]
12. Identification of potent and selective MMP-13 inhibitors.
Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR of highly selective MMP-13 inhibitors.
Li J; Rush TS; Li W; DeVincentis D; Du X; Hu Y; Thomason JR; Xiang JS; Skotnicki JS; Tam S; Cunningham KM; Chockalingam PS; Morris EA; Levin JI
Bioorg Med Chem Lett; 2005 Nov; 15(22):4961-6. PubMed ID: 16153831
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for the highly selective inhibition of MMP-13.
Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
[TBL] [Abstract][Full Text] [Related]
15. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
[TBL] [Abstract][Full Text] [Related]
16. Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.
Cherney RJ; Mo R; Meyer DT; Wang L; Yao W; Wasserman ZR; Liu RQ; Covington MB; Tortorella MD; Arner EC; Qian M; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Decicco CP
Bioorg Med Chem Lett; 2003 Apr; 13(7):1297-300. PubMed ID: 12657268
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
[TBL] [Abstract][Full Text] [Related]
18. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
[TBL] [Abstract][Full Text] [Related]
19. Bis-substituted malonic acid hydroxamate derivatives as inhibitors of human neutrophil collagenase (MMP8).
Graf von Roedern E; Brandstetter H; Engh RA; Bode W; Grams F; Moroder L
J Med Chem; 1998 Jul; 41(16):3041-7. PubMed ID: 9685244
[TBL] [Abstract][Full Text] [Related]
20. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.
Yang SM; Scannevin RH; Wang B; Burke SL; Huang Z; Karnachi P; Wilson LJ; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1140-5. PubMed ID: 18083558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
